FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced positive results from several studies evaluating the VEGF Trap-Eye in the neovascular form of age-related macular degeneration (wet AMD) and diabetic macular edema (DME). These findings were presented this week at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). The data reported at the meeting from a pre-planned interim analysis of a Phase 2 randomized study of the VEGF Trap-Eye in patients with wet AMD and a Phase 1 DME trial are available on the Regeneron website (www.regeneron.com on the Events page, under the Investor Relations heading).
